At least six organizations that claim to champion patient rights have deep financial and operational ties to Big Pharma and work to advance corporate profits. These industry front groups routinely lobby in line with the pharmaceutical industry’s priorities, challenge drug price negotiations in court briefings, and promote the industry’s interests in public statements, according to new research.

The findings are the latest example of how pharmaceutical companies are leveraging the legitimacy of patient advocacy groups to further their corporate aims, which are often in direct conflict with the patient rights such groups claim to support.

A report published this Monday by Patients for Affordable Drugs, a national patient advocacy nonprofit, reveals that six organizations ostensibly dedicated to expanding health research and health care access in fact receive significant funding from the pharmaceutical industry, have leadership with ongoing pharmaceutical industry connections, or both.